AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05688046
Drug: Immune checkpoint inhibitors plus angiogenesis inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-(L)1-based therapy plus Bevacizumab or Anlotinib
Trial: NCT05688046
Drug: Immune checkpoint inhibitors without angiogenesis inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-(L)1-based therapy
Trial: NCT01550510
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3x a week for 9 weeks
Trial: NCT00000381
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04164615
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.
Trial: NCT03542344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single rising oral dose
Trial: NCT04264637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
Trial: NCT00088699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01926509
Drug: MK-8892
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01926509
Drug: Placebo for MK-8892
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02344472
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03977155
Drug: BOS-589
RxNorm normalized name: BOS TAURUS EYE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT03977155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT04050839
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
Trial: NCT02278250
Drug: M4344 10 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 20 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 40 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 80 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 160 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 300 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 450 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 700 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 1050 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 1200 mg BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 100 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 150 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 250 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 350 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02278250
Drug: M4344 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT02007161
Drug: Diclofenac potassium 50 mg
RxNorm normalized name: diclofenac potassium 50 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium 50 mg
Trial: NCT02579759
Drug: PXT3003 dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Trial: NCT02579759
Drug: PXT3003 dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Trial: NCT02579759
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Trial: NCT02278250
Drug: M4344 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Trial: NCT03326791
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trombyl 160 mg once daily
Trial: NCT03326791
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet daily
Trial: NCT02956486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT00006337
Drug: IV Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00583531
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 2 grams TID in sachets for 4 weeks
Trial: NCT02499250
Drug: Optimal medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
Trial: NCT02049307
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01145183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo daily dosing
Trial: NCT02550366
Drug: MRI Contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI Contrast
Trial: NCT00197730
Drug: Multivitamins - vitamins B complex, C and E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
Trial: NCT00197730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
Trial: NCT00982072
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 1mg/kg maximum 60mg od
Trial: NCT03384966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for subcutaneous administration.
Trial: NCT05410314
Drug: Myo-Inositol and D-Chiro-Inositol (MIC)
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
Trial: NCT00137449
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
Trial: NCT01892189
Drug: TAK-063 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 placebo-matching tablets
Trial: NCT00853684
Drug: OXCE
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
Trial: NCT01266980
Drug: Inhaled FF/ GW642444M (200/25mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
Trial: NCT02033408
Drug: AB (antibiotics)
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.
Trial: NCT02033408
Drug: CS (corticosteroids) Only
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks
Trial: NCT01189760
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
Trial: NCT01712373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it is placebo
Trial: NCT03452345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Normal saline)
Trial: NCT03395093
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
Trial: NCT03482232
Drug: Non-steroidal anti-inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
Trial: NCT03482232
Drug: Antimicrobial agent
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
Trial: NCT03482232
Drug: Lipid-lowering drug
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
Trial: NCT03482232
Drug: Antimicrobial agent
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotics for pharyngitis (infants)
Trial: NCT03482232
Drug: Mucolytic
RxNorm normalized name: MUCOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
Trial: NCT03482232
Drug: Ibuprofen and paracetamol
RxNorm normalized name: Ibuprofen and paracetamol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with ibuprofen and paracetamol (infants)
Trial: NCT02171728
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03409198
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03409198
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT00520338
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. placebo~2. celecoxib 400 mg oral single dose
Trial: NCT01991873
Drug: Maintenance Chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01991873
Drug: mFOLFOX6 (Within re-induction phase)
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03208790
Drug: Nigella sativa buccal tablets 10mg
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
Trial: NCT03208790
Drug: Nigella sativa buccal tablets 5mg
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
Trial: NCT03208790
Drug: Placebo buccal tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules with the same color and form as the active ones but without active ingredient will be given to the patients
Trial: NCT01288794
Drug: Diuretics plus human albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
Trial: NCT01288794
Drug: Diuretics (standard medical treatment)
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive standard medical treatment (diuretics)
Trial: NCT02937519
Drug: induction Chrono-chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02937519
Drug: induction Routine-chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01454869
Drug: standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
Trial: NCT01454869
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
Trial: NCT00035464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets, twice a day for 6 months
Trial: NCT00754572
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg oral or parenteral weekly.
Trial: NCT01505088
Drug: Prednisolone Acetate (1%) Eyedrops
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone phosphate (DB14631)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate (1%) eyedrops
Trial: NCT01505088
Drug: Placebo Eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Eyedrops
Trial: NCT00347269
Drug: Psychotropic medication optimization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
Trial: NCT03577470
Drug: D/C/F/TAF Fixed-Dose Combination (FDC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
Trial: NCT04249037
Drug: Standard initiation of antiretroviral therapy (ART)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
Trial: NCT02786329
Drug: TIVA+placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
Trial: NCT03176992
Drug: SURGICEL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
Trial: NCT00528099
Drug: IMA-026
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
Trial: NCT00807807
Drug: Placebo Folic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo folic acid once a day for 6 weeks
Trial: NCT01574612
Drug: acyclovir/hydrocortisone cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream applied topically to lesion five times daily for five days
Trial: NCT04270019
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard solution of sterile normal saline.
Trial: NCT02262169
Drug: Placebo caplet of DLBS2411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo caplet of DLBS2411, twice daily
Trial: NCT02262169
Drug: DLBS2411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 DLBS2411 caplet 250 mg, twice daily
Trial: NCT03340779
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
Trial: NCT01154933
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline sq
Trial: NCT01687426
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye daily four times a day for 14 days
Trial: NCT00123942
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no